30 closest matches · ranked by relevance
Primary Ciliary Dyskinesia
Primary: Baseline MCC (Ave60Clr; Average Clearance Over 60 Minutes) — 1.4; -1.1; 7.3 percent clearance — p=0.002
Primary Ciliary Dyskinesia
Primary: Vestibular Evoked Myogenic Potentials (VEMPs) — 0; 3; 2 participants
Primary Ciliary Dyskinesia
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 52; 46; 22; 23 Participants
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
Cystic Fibrosis
Primary: Sufficient Sputum Quantity for a Pellet — 9 Participants
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Cystic Fibrosis
Primary: Chest CT (High Resolution Computed Tomography (HRCT) Score) — 3.7; 6.1 Score points
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264
Primary Immune Deficiency Disorder
Primary: Number of Participants With Different Epidemiological Features — 287; 100; 68; 56 patients
Sinusitis · Cystic Fibrosis
Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2
Cystic Fibrosis
Primary: Percent Mucociliary Clearance at 60 Minutes — 18.6; 15.4 percentage mucociliary clearance — p=0.62
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio
Cystic Fibrosis
Primary: Lung Function: Lung Clearance Index — 9; 9.7 lung clearance index
Cystic Fibrosis · Mucociliary Clearance Defect
Primary: Mucociliary Clearance-274 — 20.3; 16.8; 18.5; 19.1 percent clearance — p=0.615
Cystic Fibrosis
Primary: Change in Sputum Bacterial Culture — -0.59; -0.89 CFU/mL
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Cystic Fibrosis
Primary: Change in Sodium Conductance by Nasal Potential Difference (NPD) — -0.70; 1.81 mV
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo — NA; NA Days — p=0.0511
Neuromuscular Diseases
Primary: Change in Antibiotic Courses — 4; 1; 2.50; 1.00 Courses of antibiotics — p=<0.001
Congenital Diaphragmatic Hernia
Primary: Number of Participants With Elevated Sputum Eosinophils — 0 participants
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
COPD
Primary: Occurrence of Suboptimal PIFR — 22.7 percentage of participants
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…
COPD · Chronic Bronchitis · Emphysema
Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC
Cystic Fibrosis
Primary: The Safety and Tolerability of a Single-dose of KB001. — 7; 10; 8 Number of participants experiencing AEs
Bronchiectasis
Primary: Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29). — -2.94; -0.32 log10 of CFU per gram sputum — p=< 0.001
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
Cystic Fibrosis
Primary: FEV1 as a Measure of Lung Function — .35 percentage of liters